COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups
COEPTIS (Nasdaq: COEP) has announced the launch of COEP Venture Group, a new investment arm focused on funding startups specializing in Artificial Intelligence, Robotic Process Automation, and AI Agents. The venture group will be led by Michael Woloshin, co-founder of Recruiter.com and founder of NexGenAI Solutions Group.
The investment focus includes advanced machine learning models, AI-powered automation for workflow optimization, autonomous AI-powered assistants, and emerging technologies like blockchain applications. COEP Venture Group will provide capital, strategic mentorship, and industry network access to portfolio companies, while leveraging NexGenAI Solutions Group to provide marketing services.
This initiative expands COEPTIS's existing portfolio, which includes biopharmaceutical divisions focusing on cell therapy platforms for cancer, autoimmune, and infectious diseases, featuring assets licensed from Deverra Therapeutics and partnerships with VyGen-Bio and the Karolinska Institute.
COEPTIS (Nasdaq: COEP) ha annunciato il lancio di COEP Venture Group, un nuovo braccio d'investimento focalizzato sul finanziamento di startup specializzate in Intelligenza Artificiale, Automazione dei Processi Robotici e Agenti AI. Il gruppo di venture sarà guidato da Michael Woloshin, co-fondatore di Recruiter.com e fondatore di NexGenAI Solutions Group.
Il focus degli investimenti include modelli avanzati di machine learning, automazione alimentata da AI per l'ottimizzazione dei flussi di lavoro, assistenti autonomi alimentati da AI e tecnologie emergenti come le applicazioni blockchain. COEP Venture Group fornirà capitale, mentoring strategico e accesso a una rete di settore per le aziende del portafoglio, sfruttando NexGenAI Solutions Group per fornire servizi di marketing.
Questa iniziativa espande il portafoglio esistente di COEPTIS, che include divisioni biofarmaceutiche focalizzate su piattaforme di terapia cellulare per il cancro, malattie autoimmuni e infettive, con asset concessi in licenza da Deverra Therapeutics e partnership con VyGen-Bio e il Karolinska Institute.
COEPTIS (Nasdaq: COEP) ha anunciado el lanzamiento de COEP Venture Group, una nueva rama de inversión centrada en financiar startups especializadas en Inteligencia Artificial, Automatización de Procesos Robóticos y Agentes de IA. El grupo de capital de riesgo estará liderado por Michael Woloshin, cofundador de Recruiter.com y fundador de NexGenAI Solutions Group.
El enfoque de inversión incluye modelos avanzados de aprendizaje automático, automatización impulsada por IA para la optimización de flujos de trabajo, asistentes autónomos impulsados por IA y tecnologías emergentes como aplicaciones de blockchain. COEP Venture Group proporcionará capital, mentoría estratégica y acceso a una red de la industria para las empresas de su cartera, aprovechando a NexGenAI Solutions Group para ofrecer servicios de marketing.
Esta iniciativa amplía el portafolio existente de COEPTIS, que incluye divisiones biofarmacéuticas centradas en plataformas de terapia celular para el cáncer, enfermedades autoinmunes e infecciosas, con activos licenciados de Deverra Therapeutics y asociaciones con VyGen-Bio y el Instituto Karolinska.
COEPTIS (Nasdaq: COEP)는 COEP Venture Group의 출범을 발표했습니다. 이는 인공지능, 로봇 프로세스 자동화 및 AI 에이전트에 특화된 스타트업에 자금을 지원하는 새로운 투자 부문입니다. 이 벤처 그룹은 Recruiter.com의 공동 창립자이자 NexGenAI Solutions Group의 설립자인 Michael Woloshin이 이끌게 됩니다.
투자 초점은 고급 기계 학습 모델, 워크플로 최적화를 위한 AI 기반 자동화, 자율 AI 기반 어시스턴트 및 블록체인 애플리케이션과 같은 신흥 기술을 포함합니다. COEP Venture Group은 포트폴리오 회사에 자본, 전략적 멘토링 및 산업 네트워크 접근을 제공하고, NexGenAI Solutions Group을 활용하여 마케팅 서비스를 제공합니다.
이 이니셔티브는 COEPTIS의 기존 포트폴리오를 확장하며, 이는 암, 자가면역 및 감염성 질병을 위한 세포 치료 플랫폼에 중점을 둔 생물 제약 부문을 포함하고 있으며, Deverra Therapeutics로부터 라이선스를 받은 자산과 VyGen-Bio 및 카롤린스카 연구소와의 파트너십을 특징으로 합니다.
COEPTIS (Nasdaq: COEP) a annoncé le lancement de COEP Venture Group, un nouveau bras d'investissement axé sur le financement de startups spécialisées dans l'intelligence artificielle, l'automatisation des processus robotiques et les agents AI. Le groupe de capital-risque sera dirigé par Michael Woloshin, cofondateur de Recruiter.com et fondateur de NexGenAI Solutions Group.
Le focus d'investissement inclut des modèles avancés d'apprentissage automatique, une automatisation alimentée par l'IA pour l'optimisation des flux de travail, des assistants autonomes alimentés par l'IA et des technologies émergentes comme les applications blockchain. COEP Venture Group fournira du capital, du mentorat stratégique et un accès à un réseau industriel pour les entreprises du portefeuille, tout en s'appuyant sur NexGenAI Solutions Group pour offrir des services de marketing.
Cette initiative élargit le portefeuille existant de COEPTIS, qui comprend des divisions biopharmaceutiques axées sur des plateformes de thérapie cellulaire pour le cancer, les maladies auto-immunes et infectieuses, avec des actifs sous licence de Deverra Therapeutics et des partenariats avec VyGen-Bio et l'Institut Karolinska.
COEPTIS (Nasdaq: COEP) hat die Gründung der COEP Venture Group angekündigt, einem neuen Investitionsarm, der sich auf die Finanzierung von Startups spezialisiert hat, die sich mit Künstlicher Intelligenz, Robotic Process Automation und KI-Agenten beschäftigen. Die Venture-Gruppe wird von Michael Woloshin geleitet, dem Mitbegründer von Recruiter.com und Gründer der NexGenAI Solutions Group.
Der Investitionsfokus umfasst fortschrittliche Modelle des maschinellen Lernens, KI-gestützte Automatisierung zur Optimierung von Arbeitsabläufen, autonome KI-gestützte Assistenten und aufkommende Technologien wie Blockchain-Anwendungen. Die COEP Venture Group wird Kapital, strategische Mentorships und Zugang zu Branchennetzwerken für Portfoliounternehmen bereitstellen und dabei die NexGenAI Solutions Group nutzen, um Marketingdienstleistungen anzubieten.
Diese Initiative erweitert das bestehende Portfolio von COEPTIS, das biopharmazeutische Bereiche umfasst, die sich auf Zelltherapieplattformen für Krebs, Autoimmun- und Infektionskrankheiten konzentrieren, mit Vermögenswerten, die von Deverra Therapeutics lizenziert sind, und Partnerschaften mit VyGen-Bio und dem Karolinska-Institut.
- Expansion into high-growth AI and automation technology sectors
- Strategic diversification beyond biopharmaceutical focus
- Leveraging existing NexGenAI Solutions Group infrastructure for marketing services
- Experienced leadership with Michael Woloshin's technology background
- Additional capital requirements for new venture investments
- Potential distraction from core biopharmaceutical business
- Risk of unsuccessful investments in early-stage startups
Insights
The launch of COEP Venture Group represents a significant strategic expansion for COEPTIS, potentially transforming the company from a pure-play biotech into a hybrid technology-biotech investment vehicle. This move is particularly noteworthy given the company's relatively modest market cap of
The venture arm's structure offers several strategic advantages:
- Integration with NexGenAI Solutions Group provides portfolio companies with immediate access to marketing and automation infrastructure, creating a unique value proposition in the competitive venture capital landscape
- Focus on AI, RPA, and AI Agents aligns with growing enterprise demand for automation solutions, potentially creating valuable synergies with COEPTIS's existing biotech operations, particularly in areas like drug discovery and clinical trial optimization
- Leadership by Michael Woloshin brings proven expertise in both technology development and successful exits, as evidenced by his track record with Recruiter.com
However, this strategic shift carries notable considerations for investors:
- Resource allocation between core biotech operations and the new venture arm could strain the company's capital resources
- The venture capital space for AI/RPA is highly competitive, with established players like Sequoia and Andreessen Horowitz commanding significant advantages in deal flow and expertise
- The lack of disclosed fund size or investment parameters creates uncertainty about the scale and potential impact of this initiative
The integration of NexGenAI Solutions Group's infrastructure could provide a competitive edge in portfolio company development, potentially accelerating time-to-market and reducing operational costs for startups. This operational support model mirrors successful approaches used by venture studios, suggesting a more hands-on investment strategy that could yield higher success rates for portfolio companies.
WEXFORD, Pa., Feb. 13, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a pioneering technology company dedicated to advancing cutting-edge technologies and artificial intelligence at the forefront of innovative biotechnology therapeutic solutions, today announced the launch of COEP Venture Group, a newly established investment arm dedicated to funding and accelerating technology startups specializing in Artificial Intelligence (AI), Robotic Process Automation (RPA), and AI Agents.
COEP Venture Group aims to identify, invest in, and support high-potential startups shaping the future of automation, intelligent systems, and AI-driven enterprise solutions. By providing capital, strategic mentorship, and access to industry networks, COEP Venture Group seeks to drive technological advancements that enhance business efficiency, decision-making, and automation across multiple industries.
Empowering the Future of AI & Automation
"The launch of COEP Venture Group aligns with our vision of investing in disruptive technologies that redefine industries," said Dave Mehalick, CEO of Coeptis Therapeutics Holdings Inc. “AI-driven automation and intelligent agents are transforming the way businesses operate. Through COEP Venture Group, we are committed to supporting pioneering startups at the forefront of AI and RPA innovation,” continued Mr. Mehalick.
In addition, COEP Venture Group will leverage NexGenAI Solutions Group, which powers its latest acquisition, NexGenAI Affiliates Group, to provide marketing services to portfolio companies. This initiative ensures that startups receive not only funding but also strategic exposure and market positioning, allowing them to scale rapidly and successfully execute their business plans.
Leadership & Strategic Vision
COEP Venture Group will benefit from the expertise of Michael Woloshin, a seasoned entrepreneur with deep experience in technology, AI, and marketing automation. Michael Woloshin was the co-founder of Recruiter.com and the founder of NexGenAI Solutions Group, which powers COEP’s latest acquisition, NexGenAI Affiliates Group, where he built the technology platform enabling marketing and business automation. His leadership and insights will drive COEP Venture Group’s mission to foster innovation and expand market opportunities for emerging technology companies.
Investment Focus
COEP Venture Group will target high-growth startups that align with its investment strategy, including:
- Artificial Intelligence (AI)– Advanced machine learning models, predictive analytics, and AI-driven enterprise solutions.
- Robotic Process Automation (RPA)– AI-powered automation to streamline workflows, enhance business operations, and reduce inefficiencies.
- AI Agents & Intelligent Systems– Autonomous AI-powered assistants and decision-making frameworks optimizing complex tasks in sectors such as healthcare, finance, and enterprise automation.
- Other Emerging Technologies – Strategic investments in blockchain applications, data analytics platforms, and next-generation enterprise software that fit COEP Venture Group’s vision.
To learn more about COEP Venture Group and investment opportunities, visit our website https://coepventuregroup.com
About COEPTIS, Inc.
COEPTIS, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies (collectively "Coeptis"), is a biopharmaceutical and technology company. The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. COEPTIS is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.
Building on its core competencies, COEPTIS has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.
Headquartered in Wexford, PA, COEPTIS is dedicated to advancing its mission within the regulatory framework set forth by the FDA, ensuring that all activities align with the highest standards of compliance and patient care. For more information on COEPTIS, visit https://coeptistx.com
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the inability to recognize the anticipated benefits of the Deverra licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (3) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (4) costs related to ongoing asset development including the Deverra licensed assets and pursuing the contemplated asset development paths; (5) changes in applicable laws or regulations; (6) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (7) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.
Contacts
IR@coeptistx.com
FAQ
What is COEP Venture Group's investment focus for 2025?
How will COEP Venture Group support its portfolio companies?
Who is leading COEP Venture Group's investment strategy?
How does COEP Venture Group align with COEPTIS's existing business?
